Mortality of Patients With Sepsis Administered Piperacillin-Tazobactam vs Cefepime
JAMA Internal Medicine · 01.07.2024 · 184 (7) · 769
DOI: 10.1001/jamainternmed.2024.0581 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA Internal Medicine, erschienen am 01.07.2024. Verfasst von Rishi Chanderraj und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor. Hauptthemen laut MEDLINE: Cefepime, Piperacillin, Tazobactam Drug Combination, Anti-Bacterial Agents, Sepsis. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, CSRD VA, NIAID NIH HHS.
Themen: Sepsis
Abstract (Originalsprache)
Importance Experimental and observational studies have suggested that empirical treatment for bacterial sepsis with antianaerobic antibiotics (eg, piperacillin-tazobactam) is associated with adverse outcomes compared with anaerobe-sparing antibiotics (eg, cefepime). However, a recent pragmatic clinical trial of piperacillin-tazobactam and cefepime showed no difference in short-term outcomes at 14 days. Further studies are needed to help clarify the empirical use of these agents.
Objective
To examine the use of piperacillin-tazobactam compared with cefepime in 90-day mortality in patients treated empirically for sepsis, using instrumental variable analysis of a 15-month piperacillin-tazobactam shortage. Design, Setting, and Participants In a retrospective cohort study, hospital admissions at the University of Michigan from July 1, 2014, to December 31, 2018, including a piperacillin-tazobactam shortage period from June 12, 2015, to September 18, 2016, were examined. Adult patients with suspected sepsis treated with vancomycin and either piperacillin-tazobactam or cefepime for conditions with presumed equipoise between piperacillin-tazobactam and cefepime were included in the study. Data analysis was conducted from December 17, 2022, to April 11, 2023. Main Outcomes and Measures The primary outcome was 90-day mortality. Secondary outcomes included organ failure–free, ventilator-free, and vasopressor-free days. The 15-month piperacillin-tazobactam shortage period was used as an instrumental variable for unmeasured confounding in antibiotic selection.
Results
Among 7569 patients (4174 men [55%]; median age, 63 [IQR 52-73] years) with sepsis meeting study eligibility, 4523 were treated with vancomycin and piperacillin-tazobactam and 3046 were treated with vancomycin and cefepime. Of patients who received piperacillin-tazobactam, only 152 (3%) received it during the shortage. Treatment groups did not differ significantly in age, Charlson Comorbidity Index score, Sequential Organ Failure Assessment score, or time to antibiotic administration. In an instrumental variable analysis, piperacillin-tazobactam was associated with an absolute mortality increase of 5.0% at 90 days (95% CI, 1.9%-8.1%) and 2.1 (95% CI, 1.4-2.7) fewer organ failure–free days, 1.1 (95% CI, 0.57-1.62) fewer ventilator-free days, and 1.5 (95% CI, 1.01-2.01) fewer vasopressor-free days. Conclusions and Relevance Among patients with suspected sepsis and no clear indication for antianaerobic coverage, administration of piperacillin-tazobactam was associated with higher mortality and increased duration of organ dysfunction compared with cefepime. These findings suggest that the widespread use of empirical antianaerobic antibiotics in sepsis may be harmful.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.
- Medicine Service, Infectious Diseases Section, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.
- Weil Institute for Critical Care Research & Innovation, Ann Arbor, Michigan.
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.
- Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor.
- Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.
Förderung
- NHLBI NIH HHS
- CSRD VA
- NIAID NIH HHS
Zitieren
APA
Chanderraj, R., Admon, A. J., He, Y., Nuppnau, M., Albin, O. R., Prescott, H. C., Dickson, R. P., & Sjoding, M. W. (2024). Mortality of Patients With Sepsis Administered Piperacillin-Tazobactam vs Cefepime. JAMA Internal Medicine, 184(7), 769. https://doi.org/10.1001/jamainternmed.2024.0581
Vancouver
Chanderraj R, Admon AJ, He Y, Nuppnau M, Albin OR, Prescott HC, et al. Mortality of Patients With Sepsis Administered Piperacillin-Tazobactam vs Cefepime. JAMA Internal Medicine. 2024;184(7):769. doi:10.1001/jamainternmed.2024.0581
BibTeX
@article{Chanderraj2024,
author = {Chanderraj, Rishi and Admon, Andrew J and He, Ying and Nuppnau, Mark and Albin, Owen R and Prescott, Hallie C and Dickson, Robert P and Sjoding, Michael W},
title = {Mortality of Patients With Sepsis Administered Piperacillin-Tazobactam vs Cefepime},
journal = {JAMA Internal Medicine},
year = {2024},
volume = {184},
number = {7},
pages = {769},
doi = {10.1001/jamainternmed.2024.0581}
}
EUVIMED